EcoDrugPlus

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSMOCG00000002444
Gene Symbol: GLP1R
3 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSMOCG00000021626
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSMOCG00000021695
Gene Symbol: GCGR
3 Cross references
183 Possible Orthologues:

Glucokinase

Ensembl ID : ENSMOCG00000007909
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosidase Alpha, Acid

Ensembl ID : ENSMOCG00000020111
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Glucosylceramidase Beta

Ensembl ID : ENSMOCG00000016015
Gene Symbol: GBA
3 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSMOCG00000022383
Gene Symbol: GRIA1
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSMOCG00000011766
Gene Symbol: GRIA2
3 Cross references
321 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSMOCG00000002499
Gene Symbol: GRIA3
3 Cross references
318 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSMOCG00000011931
Gene Symbol: GRIA4
3 Cross references
324 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSMOCG00000001739
Gene Symbol: GRIN1
3 Cross references
278 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSMOCG00000003843
Gene Symbol: GRIN2A
3 Cross references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).